Plaque Psoriasis

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.

This analysis suggests intake of riboflavin, also known as vitamin B2, shows an association with patients’ risk of developing psoriasis.

These results highlight the association between nail psoriasis and various factors such as male sex and smoking.

In this analysis, investigators highlighted both the efficacy and safety regardless of previous utilization of biologic therapies.

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

These data highlight the risk level among certain patients with psoriasis of excessive sun exposure, associated commonly with tanning.

The program can indicate the severity of nail psoriasis and allow practitioners to quickly and accurately diagnose patients.

In these findings, the FamilyPso tool was validated for assessing psoriasis burdens on family members in multiple countries.

An observational study has indicated a correlation between biologic medications and a lower risk of CVD: more research is needed to determine causality.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

Test your knowledge below on pooled data from the ADORING trial program and stay up to date with clinical advancements in atopic dermatitis.

The interchangeable designation was granted to CT-P17, a biosimilar to adalimumab (Humira), for inflammatory diseases such as psoriasis.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

Our top 5 headlines spotlight developments in AI-driven care, diabetes tech, and dermatology, alongside key FDA actions in ophthalmology and nephrology.

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

In our Q1 recap for dermatology, we spotlight clinical trial data, recent updates, and advancements in therapeutic options.

This research highlights the potential of a tripeptide as a topical emollient-based cream for patients with psoriasis.

These findings were the result of a new analysis of the inflammatory characteristics associated with the efficacy sustenance of biologic medications for psoriasis.

These findings indicate that lower ambient solar radiation is linked with more frequent systemic psoriasis therapy.

In this literature review, investigators concluded that subcutaneous injections of methotrexate have some advantages over oral therapy.